Navigating Multiple Myeloma: From Newly Diagnosed to Relapsed/Refractory - Episode 3
Academic Perspectives in Front-Line Treatment Goals in Newly Diagnosed Transplant-Ineligible Multiple Myeloma
Panelists discuss how patient selection for quadruplet therapy in transplant-ineligible/deferred NDMM requires careful consideration of multiple factors, including fitness level and comorbidities, while highlighting daratumumab-VRd’s potential advantages such as subcutaneous administration and demonstrated efficacy in the CEPHEUS trial despite increased complexity and cost considerations.
Video Player is loading.
Video content above is prompted by the following:
- How do you determine which patients are best suited for quadruplet therapy?
- What outcomes and factors are critical to consider?
- MRD negativity? Depth of response? Safety? Relapse? Other?
- Share perspectives on how the Dara-VRd regimen from CEPHEUS could impact the treatment landscape for TIE or deferred NDMM.
- What advantages (ie, SC administration) does the regimen provide?
- What other benefits or challenges should be considered?
Related Content:
